Richard DiMarchi helped develop the sepsis-treating drug Xigris for Eli Lilly and Co. He also co-founded Marcadia Biotech, which Roche acquired in 2010 for an initial upfront payment of $287 million.
Early-stage venture capital has been harder and harder to come by for life sciences companies in recent years, but two Indianapolis investors are working to raise sizable funds to help fill the gap.
Are you tired of hearing about politics and the election? Then shake hands with a brother Elk, because I, too, am glad it’s over.
Indianapolis-based regulatory consulting firm Anson Group named Scott Thiel its director of connected health operations. In that role, he will help Anson’s customers commercialize wireless, mobile and networked technologies. Before joining Anson in 2011, Thiel served as a global regulatory affairs manager at Roche Diagnostics Corp. He holds degrees from Ball State University and Indiana Wesleyan University.
Anson Group named Scott Durlacher its director of compliance. Durlacher has worked with Anson since 2009, serving as the lead on several compliance projects. He holds degrees from Purdue University and Vanderbilt University.
Jeanelle Regal has been appointed director for Senior Promise, a Franciscan St. Francis Health-based program that provides insurance services to Hoosiers 50 and older. Regal received a bachelor’s in psychology from Andrews University in Michigan, and later earned a master’s in social work at Indiana University.
The departure of Keith Connors from WTHR-TV Channel 13 will leave three out of the four local network television stations without a news director.
If a biotech startup were akin to a rock band, Kristin Sherman might be the keyboardist. She’s not front-and-center on the stage, but the ballad wouldn’t be as dynamic without her pounding the chords.
Pete Kissinger hopes Phlebotics will follow in the footsteps of another of his creations, Bioanalytical Systems Inc.
Major airlines on Monday called off 38 flights departing Indianapolis to several airports in New York, Newark, Philadelphia and Washington. Airlines also canceled 36 flights scheduled to arrive in Indianapolis the same day.
Roche officials said last week that price competition and lower reimbursement rates are forcing it to make an unspecified number of cuts in its U.S. sales force and at its research and development hubs in Indianapolis and Germany.
Researchers are set to test drugs by Eli Lilly and other companies that may prevent Alzheimer’s disease after efforts to find a cure have been unsuccessful.
The real news is that the Midwest in general and Indiana in particular is bouncing back. In fact, the Midwest is not only resurgent—it is leading the national economic recovery.
Eli Lilly and Co. has apparently made major medical history by being the first to develop a drug that alters the course of Alzheimer’s disease. But whether Lilly can be the first to make major money from a disease-altering Alzheimer’s drug is still in doubt.
Eli Lilly & Co.’s solanezumab and Roche Holding AG’s gantenerumab were selected for a long-term Alzheimer’s trial run by Washington University at St. Louis scientists seeking to block the disease’s symptoms.
People listings are free. Information must be submitted at least 11 days before the Monday issue in which it is to appear. Publication of information might be delayed due to space limitations. To submit information and photos online go to www.ibj.com and use the People submissions form. Photos may be sent as jpegs, 300 dpi […]
Joyce Irwin has been named CEO of Community Health Network Foundation, the charitable arm of the Indianapolis-based Community Health Network hospital system. On Oct. 22, Irwin will replace Dr. Jeffrey Boester, who has served as interim CEO since June, following the departure of Michele Dole. Irwin was most recently national director of state government affairs, regulatory and public policy at Roche Diagnostics Corp. in Indianapolis. Before Roche, Irwin worked as a consultant on corporate public policy for Eli Lilly and Co. She holds bachelor's and master's degrees in education from Indiana University.
AIT Laboratories has named Paula Conroy its chief financial officer. Conroy most recently operated her own consulting business specializing in CFO services for privately held companies. Conroy previously worked at the U.S. Securites & Exchange Commission and Ernst & Young LLP. She holds both a bachelor’s in management and an MBA from Purdue University and is a certified public accountant.
Dr. Sarah Ali, an oncologist and hematologist, has joined Franciscan Physician Network Oncology & Hematology Specialists on the south side. Ali earned her medical degree at St. George’s University School of Medicine in Grenada, West Indies, and completed a hematology-oncology fellowship at Michigan State University.
Sean Fallon has been named chief technology officer for CNO Financial Group Inc. He most recently worked at Lincoln Financial Group, where he served as vice president for application development in its group protection division. Fallon holds a bachelor’s degree in business and finance from the University of Wisconsin at Madison and a master’s in finance from the University of Wisconsin at Milwaukee.
The Fishers-based Behavior Analysis Center for Autism hired psychologist Genae Hall as its new research director and consultant. She currently serves as the co-director of Behavior Analysis and Intervention Services. A native of California, Hall holds a bachelor’s degree in psychology from the University of California at Santa Barbara, a master’s in psychology from Western Michigan University, and a doctorate in psychology from West Virginia University.
You know things are bad in the fiercely competitive pharma industry when drugmakers start turning to each other for help. But that’s exactly what happened last week when 10 major drug companies—including Eli Lilly and Co.—joined forces to cut costs out of clinical trials.
Eli Lilly and Co. said Thursday that its cancer drug Alimta didn’t extend overall survival when combined with Roche Holding AG’s Avastin in patients with a form of lung tumor.
